The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).
Read More
The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.
Read More
The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Read More
Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).
Read More
The National Institute for Health and Care Excellence has today published draft guidance not recommending Pfizer’s Besponsa to treat some patients with leukaemia on the NHS in England and Wales.
Read More
